Novavax on Tuesday announced the first emergency use authorization of its COVID-19 vaccine for adolescents falling in the age bracket of 12-18 years in India.

As per an official statement released by Novovax, the vaccine, also known as NVX-CoV2373, is manufactured and marketed in India by the Serum Institute of India (SII) under the brand name Covovax and is the first protein-based vaccine authorized for use in this age group in India.